Skip to main content
Pixium Vision logo

Pixium Vision — Investor Relations & Filings

Ticker · ALPIX ISIN · FR001400JX97 LEI · 96950046OPLRLKKEOO08 PA Manufacturing
Open in API
Filings indexed 440 across all filing types
Latest filing 2015-01-07 Board/Management Inform…
Country FR France
Listing PA ALPIX

About Pixium Vision

https://www.pixium-vision.com/

Pixium Vision was a bioelectronics company that developed bionic vision systems to restore partial sight for patients with retinal diseases. Its core technology, the PRIMA System, is a photovoltaic subretinal implant designed to treat vision loss from advanced atrophic dry age-related macular degeneration (dry AMD). The system uses specialized glasses to project near-infrared light onto the implant, which converts the light into electrical signals to stimulate retinal cells and create a form of prosthetic vision. The company's assets, including the PRIMA technology and its ongoing European pivotal trial (PRIMAvera), were acquired by Science Corporation in late 2023. The trials and device manufacturing are now sponsored by La Science SAS.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release dated January 7, 2015, announcing a change in the company's governance structure: the separation of the roles of Chairman and CEO, with Khalid Ishaque becoming the new CEO. This type of announcement, detailing changes in senior leadership and the board structure, directly corresponds to the definition of Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2015-01-07 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 95% confidence The document is a press release titled 'Pixium Vision: sales for the first 9 months of 2014'. It provides a summary of financial performance (sales and cash flow) for a specific interim period (first nine months of 2014) and includes a section on 'Major Developments' summarizing corporate activities. While it contains financial data, it is structured as a press release (Earnings Release) rather than a formal, comprehensive Interim Report (which would typically be a longer, audited or formal regulatory filing). According to the definitions, an Earnings Release is the initial announcement of quarterly/periodical financial results containing key highlights. 9M 2014
2014-11-14 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Interim / Quarterly Report Classification · 95% confidence The document is a press release from Pixium Vision announcing its financial results for the first nine months of 2014. It includes key financial highlights such as revenue and cash flow data, as well as a summary of significant corporate events (M&A, IPO, management changes). Since it provides substantive financial data for a period shorter than a full fiscal year (nine months) and is not merely an announcement of a report's availability, it is classified as an Interim/Quarterly Report. 9M 2014
2014-11-14 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Environmental & Social Information Classification · 99% confidence The document is a press release dated October 28, 2014, announcing the company's participation in a conference ('Ophta Biotech conférence annuelle'). It discusses the company's technology (IRIS® system), clinical trials, and future commercialization plans. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed interim report (IR). It is an announcement intended for investors and the public regarding company activities and progress, which aligns best with a general Investor Presentation (IP) or a Regulatory Filing (RNS) if no better fit exists. Since it details technology, progress, and future outlook in a narrative format typical of investor communication, 'Investor Presentation' (IP) is a strong candidate, although it is structured as a press release. Given the content focuses heavily on product development, clinical status, and future market entry, it serves an investor relations purpose similar to an IP, but because it is explicitly a press release announcing participation in an external event, and not a formal presentation deck, 'Regulatory Filings' (RNS) serves as the most appropriate general category for non-standard announcements, or 'IP' if we interpret the content's purpose. However, looking closely at the definitions, this is a press release announcing participation in an event and providing business updates. It is not a formal presentation deck (IP) nor a formal financial report (ER/IR). It is a general corporate update. Since it doesn't fit the specific financial report types, and it's not a notice of a dividend (DIV) or management change (MANG), the most suitable general category for corporate news updates that aren't explicitly defined elsewhere is 'Regulatory Filings' (RNS), as it functions as a general regulatory announcement.
2014-10-28 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 90% confidence The document is a press release dated October 28, 2014, announcing that Pixium Vision will be presenting at the Ophta Biotech annual conference. It discusses the company's technology (IRIS® and PRIMA), clinical trial status, and upcoming commercial launch preparations. This type of announcement, focusing on participation in an industry event and general company updates rather than formal financial reporting (like 10-K, ER, or IR) or specific regulatory actions, fits best under a general 'Regulatory Filings' or 'Investor Presentation' category. Since it is an announcement about participation in an event and general business updates, and not a formal presentation document itself, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation material. Given the format is a press release announcing participation, RNS is the most suitable fallback for non-standard announcements. It is not a formal financial report, earnings release, or management discussion.
2014-10-28 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a short press release dated September 30, 2014, announcing that Pixium Vision will attend an investor conference on October 2 & 3, 2014, and will host investor meetings. It provides company background, product updates (IRIS®, PRIMA), and contact information. This type of announcement, which informs the market about management's schedule for meeting investors, does not fit the specific categories like Earnings Release (ER), Interim Report (IR), or Capital Update (CAP). It is a general corporate communication regarding investor relations activities. Since it is not a formal regulatory filing like a 10-K or a specific report, and it is not a transcript (CT) or a formal notice of a specific event result (DVA), the most appropriate general category for corporate updates that don't fit elsewhere is Regulatory Filings (RNS), which often serves as a catch-all for press releases concerning corporate events not covered by other specific codes.
2014-09-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.